Docoh
Loading...

LNTH Lantheus

Lantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc. and EXINI Diagnostics AB and an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, Fight and Follow™ serious medical conditions. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; AZEDRA® for the treatment of certain rare neuroendocrine tumors; and RELISTOR® for the treatment of opioid-induced constipation, which is partnered with Bausch Health Companies, Inc. The Company is headquartered in North Billerica, Massachusetts with offices in New York, New Jersey, Canada and Sweden.

Company profile

Ticker
LNTH
Exchange
CEO
Mary Heino
Employees
Incorporated
Location
Fiscal year end
Former names
Lantheus MI Holdings, Inc.
SEC CIK
Subsidiaries
Lantheus Medical Imaging, Inc. • Lantheus MI Canada, Inc. • Lantheus MI Real Estate, LLC • Lantheus MI Radiopharmaceuticals, Inc. • Lantheus MI UK Limited • Lantheus EU Limited • Progenics Pharmaceuticals, Inc. • Molecular Insight Pharmaceuticals, Inc. • Molecular Insight Limited • MNTX Royalties Sub LLC ...

LNTH stock data

(
)

Calendar

28 Jul 21
27 Oct 21
31 Dec 21
Quarter (USD)
Jun 21 Mar 21 Dec 20 Sep 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Lantheus earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 93.64M 93.64M 93.64M 93.64M 93.64M 93.64M
Cash burn (monthly) (positive/no burn) (positive/no burn) 9.51M 1.93M (positive/no burn) (positive/no burn)
Cash used (since last report) n/a n/a 37.42M 7.61M n/a n/a
Cash remaining n/a n/a 56.22M 86.03M n/a n/a
Runway (months of cash) n/a n/a 5.9 44.5 n/a n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
19 Oct 21 Robert J. Jr. Marshall Common Stock Sell Dispose S No Yes 22.95 5,000 114.75K 127,007
19 Oct 21 Etienne Montagut Common Stock Sell Dispose S No Yes 22.95 1,748 40.12K 83,594
18 Oct 21 Robert J. Jr. Marshall Common Stock Sell Dispose S No Yes 22.897 4,502 103.08K 132,007
18 Oct 21 Etienne Montagut Common Stock Sell Dispose S No Yes 22.897 2,364 54.13K 85,342
15 Oct 21 Andrea Sabens Common Stock Sell Dispose S No Yes 23.71 1,242 29.45K 64,828
15 Sep 21 Andrea Sabens Common Stock Sell Dispose S No Yes 24.55 1,242 30.49K 66,070
8 Sep 21 Etienne Montagut Common Stock Sell Dispose S No Yes 26.06 457 11.91K 87,262

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

99.6% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 190 161 +18.0%
Opened positions 48 26 +84.6%
Closed positions 19 27 -29.6%
Increased positions 65 49 +32.7%
Reduced positions 48 66 -27.3%
13F shares
Current Prev Q Change
Total value 1.81B 1.63B +11.0%
Total shares 67.33M 64.63M +4.2%
Total puts 376K 159K +136.5%
Total calls 360.8K 222.1K +62.4%
Total put/call ratio 1.0 0.7 +45.6%
Largest owners
Shares Value Change
BLK Blackrock 10.83M $299.39M +0.9%
Wellington Management 5.76M $159.08M -5.6%
Vanguard 4.38M $121.13M +1.4%
WELLINGTON TRUST Co N A 3.39M $45.79M 0.0%
TROW T. Rowe Price 2.83M $78.2M -2.5%
Investment Counselors Of Maryland 2.78M $76.82M +9.1%
STT State Street 2.71M $74.95M -0.7%
Thrivent Financial For Lutherans 2.39M $66.06M +112.7%
Millennium Management 2.15M $59.31M +135.8%
Artisan Partners Limited Partnership 2.13M $58.85M +101.2%
Largest transactions
Shares Bought/sold Change
Armistice Capital 0 -2.7M EXIT
Farallon Capital Management 0 -2.25M EXIT
Thrivent Financial For Lutherans 2.39M +1.27M +112.7%
Millennium Management 2.15M +1.24M +135.8%
Artisan Partners Limited Partnership 2.13M +1.07M +101.2%
SAMG Silvercrest Asset Management 1.03M +1.03M NEW
Polar Asset Management Partners 888.6K +888.6K NEW
Great Point Partners 0 -649.52K EXIT
Pura Vida Investments 536.87K +536.87K NEW
Adage Capital Partners GP, L.L.C. 500K +500K NEW

Financial report summary

?
Risks
  • Ultrasound enhancing agents may cause side effects which could limit our ability to sell DEFINITY.
  • In the U.S., we are heavily dependent on a few large customers to generate a majority of our revenues for our nuclear medical imaging products. Outside of the U.S., we rely primarily on distributors to generate a substantial portion of our revenue.
  • The CVRs we issued as part of the Progenics Acquisition may result in substantial future payments and could divert the attention of our management; in addition, the actual payments made in connection with the CVRs, if any, may not be consistent with the estimated fair value of the CVRs that we are required to prepare for accounting purposes.
Management Discussion
  • The decrease in U.S. segment revenues during the year ended December 31, 2020, as compared to the prior year is primarily due to COVID-19 related business losses which include a $4.5 million decrease in DEFINITY revenue and a $2.8 million decrease in TechneLite revenue. Additionally, rebates and allowances increased $2.5 million. Other nuclear revenue increased $0.6 million driven by the addition of Progenics revenue portfolio, which was nearly offset by a reduction in Xenon volume.
  • The increase in International segment revenues during the year ended December 31, 2020, as compared to the prior year is primarily due to a $2.5 million higher TechneLite revenue as a result of resolution of supplier disruptions and opportunistic incremental demand, partially offset by a decrease in revenue in other nuclear products driven by COVID-19 demand losses.
  • Estimates for rebates and allowances represent our estimated obligations under contractual arrangements with third parties. Rebate accruals and allowances are recorded in the same period the related revenue is recognized, resulting in a reduction to revenue and the establishment of a liability which is included in accrued expenses. These rebates and allowances result from performance-based offers that are primarily based on attaining contractually specified sales volumes and growth, Medicaid rebate programs for our products, administrative fees of group purchasing organizations and certain distributor related commissions. The calculation of the accrual for these rebates and allowances is based on an estimate of the third-party’s buying patterns and the resulting applicable contractual rebate to be earned over a contractual period.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: AB, aPROMISE, awaiting, biochemical, Cohort, communicability, CONDOR, conventional, correct, Diego, disagreement, emission, ERTC, EXINI, heading, lapse, largest, Los, metropolitan, Midwest, nationwide, Northwest, OSPREY, piflufolastat, positron, PYLARIFY, recede, resurgence, RLS, size, Southeast, Southwest, statute, tomography, turn
Removed: aforementioned, calendar, capability, certificate, composite, dependence, enable, enabling, EP, evolving, fluorine, localize, longer, morale, motivate, nature, newly, OIC, pathology, priority, reliably, retained, robust, tested, truth